How is a high-dose dexamethasone suppression test performed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

How to Perform a High-Dose Dexamethasone Suppression Test

The high-dose dexamethasone suppression test (HDDST) is performed using either an overnight 8 mg protocol or a 2-day protocol with 2 mg every 6 hours (total 8 mg over 48 hours), with the overnight test being simpler and equally effective for differentiating Cushing's disease from other causes of ACTH-dependent Cushing's syndrome.

Overnight 8 mg Protocol (Preferred for Simplicity)

Administration:

  • Give 8 mg dexamethasone orally between 2300-2400 hours (11 PM-midnight)
  • Measure serum cortisol the following morning at 0800-0900 hours 1, 2

Interpretation:

  • >50% suppression of morning cortisol from baseline = Cushing's disease (sensitivity 92-95%, specificity 100%) 3, 2
  • <50% suppression = suggests ectopic ACTH syndrome or adrenal tumor
  • Some protocols use >80% suppression for higher specificity, but this reduces sensitivity to 62% 3

Key Technical Points:

  • Obtain baseline morning cortisol (0800-0900 h) on the day before testing 4
  • Multiple sampling times (0700,0800,0900,1000 h) can improve accuracy 4
  • Consider measuring dexamethasone levels simultaneously to confirm adequate absorption and rule out false positives 5

2-Day Low-Dose Protocol (48-hour, 2 mg every 6 hours)

Administration:

  • Give 0.5 mg dexamethasone every 6 hours for 48 hours (at 0900,1500,2100,0300 h)
  • Begin at 0900 h on day 1
  • Measure serum cortisol at 0900 h on day 3 (6 hours after last dose) 1

Pediatric Dosing:

  • >40 kg: Use adult protocol and cutoff (≥50 nmol/L or ≥1.8 μg/dL)
  • <40 kg: Adjust to 30 μg/kg/day in divided doses 6, 1

Interpretation:

  • Cortisol <50 nmol/L (<1.8 μg/dL) = normal suppression
  • Cortisol ≥50 nmol/L (≥1.8 μg/dL) = abnormal, suggests Cushing's syndrome 6, 1

Alternative: Very High-Dose Protocol (32 mg)

For patients who fail to suppress with 8 mg dexamethasone, a 32 mg protocol (4 doses of 8 mg over 24 hours) can be considered 7:

  • Measure urinary free cortisol (UFC) rather than serum cortisol
  • >50% suppression of UFC suggests Cushing's disease
  • This protocol improved sensitivity from 58% (8 mg test) to 84% (32 mg test) in refractory cases 7

Critical Monitoring and Pitfalls

False Positives (inadequate suppression in normal individuals):

  • CYP3A4 inducers (phenobarbital, carbamazepine, rifampin, St. John's wort) increase dexamethasone metabolism 1, 5
  • Rapid GI transit, chronic diarrhea, celiac disease reduce absorption 5
  • Elevated CBG from oral estrogens, pregnancy, hepatitis increases total cortisol 5
  • Measure dexamethasone levels if results are equivocal 5

False Negatives (suppression despite Cushing's disease):

  • CYP3A4 inhibitors (fluoxetine, cimetidine, diltiazem) increase dexamethasone bioavailability 5
  • Decreased CBG/albumin (nephrotic syndrome) lowers total cortisol 5

Drug Interactions to Avoid:

  • Indomethacin can cause false-negative results 8
  • Adjust interpretation in patients on medications affecting dexamethasone metabolism 1

Practical Algorithm

  1. Confirm hypercortisolism first using screening tests (24-hour UFC, late-night salivary cortisol, or low-dose DST) 9

  2. Confirm ACTH-dependent with morning plasma ACTH >1.1 pmol/L (>5 ng/L) 6

  3. Perform overnight 8 mg HDDST:

    • Give 8 mg dexamethasone at 2300 h
    • Measure cortisol at 0800 h next morning
    • >50% suppression → Cushing's disease (proceed to pituitary MRI)
    • <50% suppression → Consider ectopic ACTH or repeat with 32 mg protocol

  4. If non-diagnostic, combine with CRH stimulation test (>20% cortisol increase suggests pituitary source) 6

  5. If still uncertain, proceed to bilateral inferior petrosal sinus sampling (BIPSS) 6

Important Caveats

  • The HDDST is not a screening test—only use after confirming hypercortisolism 9
  • Sensitivity is limited: 8 mg test misses 5-36% of Cushing's disease cases depending on cutoff used 3
  • Combining tests improves accuracy: Using both overnight 8 mg and 2-day protocols together achieves 91% sensitivity with 100% specificity 4
  • ACTH measurement during HDDST adds no diagnostic value compared to cortisol alone 4
  • For adrenal incidentalomas, use the 1 mg overnight DST instead (cortisol >1.8 μg/dL suggests autonomous secretion) 10, 9

References

1
Guideline

the diagnosis of cushing's syndrome: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2008

3
Research

Assessment of the utility of the high-dose dexamethasone suppression test in confirming the diagnosis of Cushing disease.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2012

9
Guideline

the american association of clinical endocrinologists and american association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2009

10
Guideline

primary aldosteronism: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2025

Related Questions

What is the recommended approach for an equivocal low-dose dexamethasone suppression test?
What are the elimination half‑life and biological half‑life of dexamethasone?
What is the appropriate intramuscular (IM) dosing, technique, and precautions for dexamethasone administration?
What intramuscular dexamethasone dose should be used for vomiting when oral intake is impossible and intravenous access is unavailable?
Can dexamethasone be administered intramuscularly for breakthrough vomiting after first- and second-line antiemetic failure?
What medications should be given to an asymptomatic patient who tests positive for respiratory syncytial virus (RSV) by polymerase chain reaction (PCR)?
What are the Class A carbapenemases?
Which patients should receive antibiotic prophylaxis before dental procedures to prevent infective endocarditis?
Should a pregnant patient with a reactive rapid plasma reagin (RPR) screening test be treated with benzathine penicillin G?
How should vomiting associated with varicella (chickenpox) be treated?
What are the recommended cancer screening and risk‑reduction measures for a patient with a pathogenic BRCA1 or BRCA2 mutation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.